The AI system can detect a larger number of high-risk patients across France, Germany, Italy, Spain, and the UK by 2030.

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

Owkin Inc. partnered with Astrazeneca plc to develop an artificial intelligence (AI)-powered tool to pre-screen for germline BRCA mutations (gBRCAm) in breast cancer directly from digitized pathology ...

Inn from the Cold will be announcing a major expansion of services aimed at providing enhanced support to vulnerable Calgary families, to now include expectant mothers. Full details will be revealed ...

Alfa Laval will release third quarter earnings on 24 October at 07:30 am CET. The conference call will start at 09:00 am CET. The conference call is hosted by Alfa Laval's President and CEO Tom Erixon ...

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient ...

Tagrisso reduces disease progression or death risk by 84% compared to placebo. More than 200,000 people are diagnosed with lung cancer in the U.S. each year, with NSCLC being the most common type.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...